COVID-19

Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities

Disclosure of potential conflict of interest: Z.-R. M. Thomas has received funding for congress attendance from Sanofi. D. Jamiolkowski has received funding for congress attendance from Stallergenes. E. Steveling-Klein has a transfer of value agreement with Bencard and has received funding for congress attendance from ALK. K. S. Hofmeier has received funding from Allergopharma, Sanofi-Aventis, Shire, and Novartis. K. Hartmann has received research funding from Euroimmun and consultancy or lecture fees from Allergopharma, ALK-Abelló, Blueprint, Deciphera, Menarini, Novartis, and Takeda. The rest of the authors declare that they have no relevant conflicts of interest.

These authors contributed equally to this work.

Joint senior authorship.